34
total announcements
AARTIDRUGS.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹3,644 Cr
P/E (TTM)
19.1
P/E (Forward)
14.3
EPS (TTM)
₹20.93
52W Low
₹318.95
52W High
₹534.00
Dividend Yield
0.50%
Beta
0.31
Price / Book
2.4
Debt / Equity
37.2
Revenue (TTM)
₹2,678 Cr
Gross Margin
37.52%
Operating Margin
11.46%
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about Crisil ESG Rating, which has assigned an Environmental, Social, and Governance (ESG) Rating of 'Crisil ESG 61' (Strong) for the Company based on the data pertaining to FY 2025-26.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018. The company has received a confirmation certificate from MUFG Intime India Private Limited, Registrar and Transfer Agent, for the quarter ended September 30, 2026.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the authorized persons for determining materiality of an event or information and making disclosures to Stock Exchanges, as per Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the resignation of a Director/KMP/SMP.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about change in Management. Shri Prakash M. Patil has ceased to hold the positions of Chairman, Managing Director and Chief Executive Officer with effect from September 30, 2026. Shri Adhish P. Patil has relinquished the position of Chief Financial Officer with effect from September 30, 2026, and has been promoted to the position of Managing Director with effect from October 1, 2026.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, from October 1, 2026 until the expiry of 48 hours after the declaration of Financial Results for the quarter and half year ended September 30, 2026.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange regarding Change in Director(s) of the company. The company has appointed new directors and made changes to existing directorships.
Aarti Drugs Limited
Aarti Drugs Limited has submitted the Exchange a copy Scrutinizer's report of Annual General Meeting held on September 26, 2026, and informed the Exchange regarding voting results.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange regarding 'Presentation made to the shareholders at 41st AGM'. The company has attached the presentation made to the shareholders at the 41st Annual General Meeting held on September 26, 2026, for the records.
Aarti Drugs Limited
Aarti Drugs Limited held its 41st Annual General Meeting on September 26, 2026, through video conferencing. The meeting was attended by 93 members, and the requisite quorum was present. The Chairman and Board Members made presentations, and the shareholders voted on various resolutions.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the completion of dispatch of Annual Report for the Financial Year 2025-26 and the Notice of the 41st Annual General Meeting scheduled to be held on September 26, 2026.
Aarti Drugs Limited
Aarti Drugs Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26, as required by SEBI regulations.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 26, 2026, along with the Annual Report for the Financial Year 2025-26.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about a copy of newspaper publication regarding the 41st Annual General Meeting scheduled to be held on September 26, 2026.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 27, 2026, where the Board of Directors approved the 'Aarti Drugs Limited Performance Stock Option Plan 2026' to grant not exceeding 8,00,000 Performance Stock Options to eligible employees.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, from August 25, 2026, till August 29, 2026, ahead of a Board meeting on August 27, 2026, to consider the 'Aarti Drugs Limited – Performance Stock Option Plan 2026'.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting on August 20, 2026, in Mumbai, where company officials will discuss publicly available information.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange that the Hon'ble Supreme Court of India has dismissed the Special Leave Petition filed by the GST Department, disposing of the matter in favour of the Company.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the transcript of Q1 FY27 Earning Conference call, which discussed the company's financial results and operational performance for the quarter ended 30th June 2026.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the schedule of an analyst/institutional investor meet.